🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

33 results for “Otsuka Beijing Research Institute” Clear

  1. AVP-786 matching Placebo, AVP-786, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  2. AVP-786 matching placebo, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  3. Aripiprazole

    Otsuka Beijing Research Institute

    Bipolar I

    phase 3 small molecule completed

    1 trial

  4. Aripiprazole IM Depot

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  5. Delamanid + OBR

    Otsuka Beijing Research Institute

    Multidrug-resistant Tuberculosis

    phase 3 small molecule completed

    1 trial

  6. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial

  7. JNT-517 Placebo, JNT-517, JNT-517

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  8. Jinarc 30 mg tablets, Tolvaptan, Jinarc 15 mg tablets, Samsca 7.5 mg tablets

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  9. Sibeprenlimab 400 mg

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  10. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  11. Tolvaptan

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  12. Tolvaptan

    Otsuka Beijing Research Institute

    Cardiac Edema

    phase 3 small molecule completed

    1 trial

  13. DIABECELL(R)

    Otsuka Beijing Research Institute

    Type 1 Diabetes

    phase 2 other completed

    1 trial

  14. Delamanid

    Otsuka Beijing Research Institute

    Tuberculosis, Multidrug-Resistant

    phase 2 small molecule completed

    1 trial

  15. Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 2 small molecule completed

    1 trial

  16. JNT-517 Suspension

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

  17. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  18. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  19. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  20. 100 mg Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 1 small molecule completed

    1 trial

  21. A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

    Otsuka Beijing Research Institute

    Tuberculosis

    phase 1 other active

    1 trial

  22. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Beijing Research Institute

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  23. A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with autoimmune disease(s)

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

  24. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources